The emerging potential of autophagy-based therapies in the treatment of cystic fibrosis lung infections

Autophagy

Volumn 10, Issue 3, 2014, Pages 538-547

  Junkins, Robert D ^a,b,c   McCormick, Craig ^a,c   Lin, Tong Jun ^a,b,c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b IWK HEALTH CENTRE   (Canada)

^c Beatrice Hunter Cancer Research Institute   (Canada)

Author keywords

A. fumigatus; Autophagy; B. cepacia; BECN1; Cystic fibrosis; H. influenza; Non tuberculosis mycobacterium; P. aeruginosa; Rapamycin; S. aureus; TGM2

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; AUTOPHAGY; AUTOPHAGY RESTORATION THERAPY; BACTERIAL COLONIZATION; BACTERIUM; CHRONIC INFLAMMATION; CYSTIC FIBROSIS; DISEASE PREDISPOSITION; FUNCTIONAL DISEASE; FUNGUS; HEALTH SURVEY; HIGH RISK PATIENT; HOST RESISTANCE; HUMAN; INFECTION CONTROL; LOWER RESPIRATORY TRACT; LUNG INFECTION; MUCUS SECRETION; MULTIDRUG RESISTANCE; NONHUMAN; OPPORTUNISTIC INFECTION; PATHOGEN CLEARANCE; PNEUMONIA; ANIMAL; BACTERIAL PNEUMONIA; DRUG EFFECTS; IMMUNOLOGY; MAST CELL; PHYSIOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

ANIMALS; AUTOPHAGY; HUMANS; MAST CELLS; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84896957356     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.27750     Document Type: Article

References (45)

1. Canada CF. Canadia Cystic Fibrosis Patient Data Registry 2010. 2012
2. Foundation CF. Patient Registry Annual Data Report 2011. 2012
3. Luciani A, Villella VR, Esposito S, Brunetti-Pierri N, Medina D, Settembre C, Gavina M, Pulze L, Giardino I, Pettoello-Mantovani M, et al. Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat Cell Biol 2010; 12:863- 75; PMID:20711182; http://dx.doi.org/10.1038/ncb2090
4. Liu G, Bi Y, Wang R, Wang X. Self-eating and selfdefense: autophagy controls innate immunity and adaptive immunity. J Leukoc Biol 2013; 93:511- 9; PMID:23271703; http://dx.doi.org/10.1189/jlb.0812389
5. Knodler LA, Celli J. Eating the strangers within: host control of intracellular bacteria via xenophagy. Cell Microbiol 2011; 13:1319-27; PMID:21740500; http://dx.doi.org/10.1111/j.1462-5822.2011.01632.x
6. Sanjuan MA, Dillon CP, Tait SW, Moshiach S, Dorsey F, Connell S, Komatsu M, Tanaka K, Cleveland JL, Withoff S, et al. Toll-like receptor signalling in macrophages links the autophagy pathway to phagocytosis. Nature 2007; 450:1253-7; PMID:18097414; http://dx.doi.org/10.1038/nature06421
7. Junkins RD, Shen A, Rosen K, McCormick C, Lin TJ. Autophagy enhances bacterial clearance during P. aeruginosa lung infection. PLoS One 2013; 8:e72263; PMID:24015228; http://dx.doi.org/10.1371/journal. pone.0072263
8. Dupuis A, Hamilton D, Cole DE, Corey M. Cystic fibrosis birth rates in Canada: a decreasing trend since the onset of genetic testing. J Pediatr 2005; 147:312- 5; PMID:16182667; http://dx.doi.org/10.1016/j. jpeds.2005.06.043
9. Maiuri L, Luciani A, Giardino I, Raia V, Villella VR, D'Apolito M, Pettoello-Mantovani M, Guido S, Ciacci C, Cimmino M, et al. Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPARgamma down-regulation. J Immunol 2008; 180:7697-705; PMID:18490773
10. Luciani A, Villella VR, Vasaturo A, Giardino I, Raia V, Pettoello-Mantovani M, D'Apolito M, Guido S, Leal T, Quaratino S, et al. SUMOylation of tissue transglutaminase as link between oxidative stress and inflammation. J Immunol 2009; 183:2775- 84; PMID:19625650; http://dx.doi.org/10. 4049/jimmunol.0900993
11. Mayer ML, Blohmke CJ, Falsafi R, Fjell CD, Madera L, Turvey SE, Hancock RE. Rescue of dysfunctional autophagy attenuates hyperinflammatory responses from cystic fibrosis cells. J Immunol 2013; 190:1227- 38; PMID:23264659; http://dx.doi.org/10.4049/jimmunol.1201404
12. Abdulrahman BA, Khweek AA, Akhter A, Caution K, Kotrange S, Abdelaziz DH, Newland C, Rosales- Reyes R, Kopp B, McCoy K, et al. Autophagy stimulation by rapamycin suppresses lung inflammation and infection by Burkholderia cenocepacia in a model of cystic fibrosis. Autophagy 2011; 7:1359- 70; PMID:21997369; http://dx.doi.org/10.4161/auto.7.11.17660
13. Deretic V. Autophagy: an emerging immunological paradigm. J Immunol 2012; 189:15-20; PMID:22723639; http://dx.doi.org/10.4049/jimmunol.1102108
14. Garcia-Medina R, Dunne WM, Singh PK, Brody SL. Pseudomonas aeruginosa acquires biofilm-like properties within airway epithelial cells. Infect Immun 2005; 73:8298-305; PMID:16299327; http://dx.doi.org/10.1128/IAI.73.12.8298-8305. 2005 (Pubitemid 41740320)
15. Yuan K, Huang C, Fox J, Laturnus D, Carlson E, Zhang B, Yin Q, Gao H, Wu M. Autophagy plays an essential role in the clearance of Pseudomonas aeruginosa by alveolar macrophages. J Cell Sci 2012; 125:507-15; PMID:22302984; http://dx.doi.org/10.1242/jcs.094573
16. Barbieri AM, Sha Q, Bette-Bobillo P, Stahl PD, Vidal M. ADP-ribosylation of Rab5 by ExoS of Pseudomonas aeruginosa affects endocytosis. Infect Immun 2001; 69:5329-34; PMID:11500402; http://dx.doi.org/10.1128/IAI.69.9.5329-5334. 2001 (Pubitemid 32786464)
17. Ravikumar B, Imarisio S, Sarkar S, O'Kane CJ, Rubinsztein DC. Rab5 modulates aggregation and toxicity of mutant huntingtin through macroautophagy in cell and fly models of Huntington disease. J Cell Sci 2008; 121:1649-60; PMID:18430781; http://dx.doi.org/10.1242/jcs.025726 (Pubitemid 351911822)
18. Heimer SR, Evans DJ, Stern ME, Barbieri JT, Yahr T, Fleiszig SM. Pseudomonas aeruginosa utilizes the type III secreted toxin ExoS to avoid acidified compartments within epithelial cells. PLoS One 2013; 8:e73111; PMID:24058462; http://dx.doi.org/10.1371/journal.pone.0073111
19. Seddon P, Fidler K, Raman S, Wyatt H, Ruiz G, Elston C, Perrin F, Gyi K, Bilton D, Drobniewski F, et al. Prevalence of nontuberculous mycobacteria in cystic fibrosis clinics, United Kingdom, 2009. Emerg Infect Dis 2013; 19:1128-30; PMID:23764198
20. Sohn H, Kim HJ, Kim JM, Jung Kwon O, Koh WJ, Shin SJ. High virulent clinical isolates of Mycobacterium abscessus from patients with the upper lobe fibrocavitary form of pulmonary disease. Microb Pathog 2009; 47:321-8; PMID:19800962; http://dx.doi.org/10.1016/j.micpath.2009.09.010
21. Renna M, Schaffner C, Brown K, Shang S, Tamayo MH, Hegyi K, Grimsey NJ, Cusens D, Coulter S, Cooper J, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 2011; 121:3554- 63; PMID:21804191; http://dx.doi.org/10.1172/JCI46095
22. Murphy TF, Faden H, Bakaletz LO, Kyd JM, Forsgren A, Campos J, Virji M, Pelton SI. Nontypeable Haemophilus influenzae as a pathogen in children. Pediatr Infect Dis J 2009; 28:43-8; PMID:19057458; http://dx.doi.org/10.1097/INF. 0b013e318184dba2
23. Morey P, Cano V, Martí-Lliteras P, López-Gómez A, Regueiro V, Saus C, Bengoechea JA, Garmendia J. Evidence for a non-replicative intracellular stage of nontypable Haemophilus influenzae in epithelial cells. Microbiology 2011; 157:234-50; PMID:20929955; http://dx.doi.org/10.1099/mic.0. 0404510
24. Kyrmizi I, Gresnigt MS, Akoumianaki T, Samonis G, Sidiropoulos P, Boumpas D, Netea MG, van de Veerdonk FL, Kontoyiannis DP, Chamilos G. Corticosteroids block autophagy protein recruitment in Aspergillus fumigatus phagosomes via targeting dectin-1/Syk kinase signaling. J Immunol 2013; 191:1287-99; PMID:23817424; http://dx.doi.org/10.4049/jimmunol.1300132
25. Petti CA, Fowler VG Jr. Staphylococcus aureus bacteremia and endocarditis. [vii.]. Cardiol Clin 2003; 21:219-33, vii; PMID:12874895; http://dx.doi.org/10.1016/S0733-8651(03)000304
26. Schnaith A, Kashkar H, Leggio SA, Addicks K, Krönke M, Krut O. Staphylococcus aureus subvert autophagy for induction of caspase-independent host cell death. J Biol Chem 2007; 282:2695-706; PMID:17135247; http://dx.doi.org/10.1074/jbc. M609784200 (Pubitemid 47076780)
27. Jarry TM, Cheung AL. Staphylococcus aureus escapes more efficiently from the phagosome of a cystic fibrosis bronchial epithelial cell line than from its normal counterpart. Infect Immun 2006; 74:2568- 77; PMID:16622192; http://dx.doi.org/10.1128/IAI.74.5.2568-2577.2006 (Pubitemid 43672964)
28. Rubinsztein DC, Codogno P, Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov 2012; 11:709- 30; PMID:22935804; http://dx.doi.org/10.1038/nrd3802
29. Abdulrahman BA, Khweek AA, Akhter A, Caution K, Tazi M, Hassan H, Zhang Y, Rowland PD, Malhotra S, Aeffner F, et al. Depletion of the ubiquitin-binding adaptor molecule SQSTM1/p62 from macrophages harboring cftr ΔF508 mutation improves the delivery of Burkholderia cenocepacia to the autophagic machinery. J Biol Chem 2013; 288:2049-58; PMID:23148214; http://dx.doi.org/10.1074/jbc. M112.411728
30. Shaw SY, Tran K, Castoreno AB, Peloquin JM, Lassen KG, Khor B, Aldrich LN, Tan PH, Graham DB, Kuballa P, et al. Selective modulation of autophagy, innate immunity, and adaptive immunity by small molecules. ACS Chem Biol 2013; 8:2724- 33; PMID:24168452; http://dx.doi.org/10.1021/cb400352d
31. Sundaramurthy V, Barsacchi R, Samusik N, Marsico G, Gilleron J, Kalaidzidis I, Meyenhofer F, Bickle M, Kalaidzidis Y, Zerial M. Integration of chemical and RNAi multiparametric profiles identifies triggers of intracellular mycobacterial killing. Cell Host Microbe 2013; 13:129-42; PMID:23414754; http://dx.doi.org/10.1016/j.chom.2013.01.008
32. Karapetyan YE, Sferrazza GF, Zhou M, Ottenberg G, Spicer T, Chase P, Fallahi M, Hodder P, Weissmann C, Lasmézas CI. Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents. Proc Natl Acad Sci U S A 2013; 110:7044-9; PMID:23576755; http://dx.doi.org/10.1073/pnas.1303510110
33. Vu K, Gelli A. Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii. Med Mycol 2010; 48:255-62; PMID:19572230; http://dx.doi.org/10.3109/ 13693780903081968
34. Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ Jr. A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol 2006; 2:415- 6; PMID:16816845; http://dx.doi.org/10.1038/nchembio806
35. Shoji-Kawata S, Sumpter R, Leveno M, Campbell GR, Zou Z, Kinch L, Wilkins AD, Sun Q, Pallauf K, MacDuff D, et al. Identification of a candidate therapeutic autophagy-inducing peptide. Nature 2013; 494:201-6; PMID:23364696; http://dx.doi.org/10.1038/nature11866
36. Galli F, Battistoni A, Gambari R, Pompella A, Bragonzi A, Pilolli F, Iuliano L, Piroddi M, Dechecchi MC, Cabrini G; Working Group on Inflammation in Cystic Fibrosis. Oxidative stress and antioxidant therapy in cystic fibrosis. Biochim Biophys Acta 2012; 1822:690-713; PMID:22226887; http://dx.doi.org/10. 1016/j.bbadis.2011.12.012
37. Villella VR, Esposito S, Maiuri MC, Raia V, Kroemer G, Maiuri L. Towards a rational combination therapy of cystic fibrosis: How cystamine restores the stability of mutant CFTR. Autophagy 2013; 9:1431- 4; PMID:23800975; http://dx.doi.org/10.4161/auto.25517
38. Luciani A, Villella VR, Esposito S, Gavina M, Russo I, Silano M, Guido S, Pettoello-Mantovani M, Carnuccio R, Scholte B, et al. Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on ΔF508 cystic fibrosis transmembrane conductance regulator. Autophagy 2012; 8:1657-72; PMID:22874563; http://dx.doi.org/10.4161/auto.21483
39. Grosso H, Mouradian MM. Transglutaminase 2: biology, relevance to neurodegenerative diseases and therapeutic implications. Pharmacol Ther 2012; 133:392-410; PMID:22212614; http://dx.doi.org/10.1016/j.pharmthera.2011.12.003
40. Ahner A, Gong X, Frizzell RA. Cystic fibrosis transmembrane conductance regulator degradation: cross-talk between the ubiquitylation and SUMOylation pathways. FEBS J 2013; 280:4430- 8; PMID:23809253; http://dx.doi.org/10.1111/ febs.12415
41. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K Jr., Pal A, Bornmann WG, Chiao PJ, Huang P, et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006; 66:3773-81; PMID:16585204; http://dx.doi.org/10.1158/0008-5472. CAN-05-2961
42. Lee JH, Mahendran A, Yao Y, Ngo L, Venta-Perez G, Choy ML, Kim N, Ham WS, Breslow R, Marks PA. Development of a histone deacetylase 6 inhibitor and its biological effects. Proc Natl Acad Sci U S A 2013; 110:15704-9; PMID:24023063; http://dx.doi.org/10.1073/pnas.1313893110
43. Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012; 119:2579-89; PMID:22262760; http://dx.doi.org/10.1182/blood-2011-10-387365
44. Roger T, Lugrin J, Le Roy D, Goy G, Mombelli M, Koessler T, Ding XC, Chanson AL, Reymond MK, Miconnet I, et al. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 2011; 117:1205- 17; PMID:20956800; http://dx.doi.org/10.1182/blood-2010-05- 284711
45. Lee JY, Koga H, Kawaguchi Y, Tang W, Wong E, Gao YS, Pandey UB, Kaushik S, Tresse E, Lu J, et al. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J 2010; 29:969-80; PMID:20075865; http://dx.doi.org/10.1038/emboj.2009.405